Wow!
It matters not to PER
Why?
1) Boys that can access the gene therapy drug will get it
others will use other therapies..
2)The cost $3.2 million will be a stumbling block
3) US clinicians are skeptical re efficacy
4)Sarepta is yet to make a profit from the other exon skipping drug
5)Gene therapy has still got a long way to go before it’s widely accepted
6) All in all PER will continue with its path forward
Other exon skipping drugs will use combination therapies.. eg Atl1102
.
https://finance.yahoo.com/news/sarepta-therapeutics-announces-expanded-us-210200030.html
FDA approves Sareptas Srp901 for the whole population
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.786M | |||
| Open | High | Low | Value | Volume |
| 0.9¢ | 0.9¢ | 0.9¢ | $1.1K | 126.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 6777725 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 1490666 | 6 |
View Market Depth
| Last trade - 13.05pm 11/07/2025 (20 minute delay) ? |
| PER (ASX) Chart |